---
title: "Weekly Recap | Dermata Therapeutics -15.69%, Tome news fails to hold gains"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302170411.md"
description: "Dermata Therapeutics (DRMA) fell 15.69% this week to close at $0.86, while the S&P 500 lost 1.95%, leaving the stock about 13.74 percentage points behind the benchmark. Shares declined from Monday through Wednesday, touching a weekly low of $0.6032 on Wednesday. On Thursday, a positive Tome cosmetic study result sparked a surge, with volume spiking to roughly 171 million shares and the price briefly reaching $1.18."
datetime: "2026-10-17T07:03:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302170411.md)
  - [en](https://longbridge.com/en/news/302170411.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302170411.md)
generator: "portal-rs"
---

# Weekly Recap | Dermata Therapeutics -15.69%, Tome news fails to hold gains

## The Week

Dermata Therapeutics (DRMA) fell 15.69% this week to close at $0.86, while the S&P 500 lost 1.95%, leaving the stock about 13.74 percentage points behind the benchmark. Shares declined from Monday through Wednesday, touching a weekly low of $0.6032 on Wednesday. On Thursday, a positive Tome cosmetic study result sparked a surge, with volume spiking to roughly 171 million shares and the price briefly reaching $1.18. The stock gave back most of that gain on Friday, ending the week with a rally-and-fade pattern.

## Key Events

On Thursday pre-market, Dermata announced positive topline results from a cosmetic study evaluating its Tome foundational treatment. The stock climbed sharply during regular trading, with intraday reports noting gains above 40% and a place among the day’s top gainers. By Friday pre-market, the shares pulled back, trading down more than 8% at one point. No earnings release or major regulatory announcement appeared during the week, so the price action was closely tied to this single product news item.

## Analyst Ratings

One broker covers the stock, rating it Overweight. The consensus rating is Buy, with a consensus target price of $4.00, implying roughly 365.12% upside from the current price. The target price range is also $4.00, so there is no dispersion across the single estimate. Within the biotechnology industry, DRMA ranks 493rd out of 509 names by analyst rating position, placing it in the lower band of the group.

## The Week Ahead

Next week brings a run of US macro data: the NAHB housing market index on Monday, housing starts and building permits on Tuesday, and EIA crude oil inventory reports on Wednesday. There are no disclosed company-specific events on DRMA’s calendar, so the main watch item is whether the Tome study news leads to further clinical or commercial disclosures. Market-level housing and energy data may also set the tone for small-cap risk appetite.

## In Short

The week’s story was a product-driven single-day surge that failed to hold, leaving DRMA down for the week overall. The lone analyst’s Buy rating and $4.00 target sit well above the current price, while the latest session’s money flow shows small and medium orders as net buyers and large orders as net sellers, pointing to a split in positioning. The question ahead is whether the Tome news can turn into sustained price support or whether the stock remains in a fade after headline-driven spikes.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [DRMA.US](https://longbridge.com/en/quote/DRMA.US.md)

## Related News & Research

- [Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment | DRMA Stock News](https://longbridge.com/en/news/301975533.md)
- [SK Hynix to announce steps to boost shareholder returns on Wednesday](https://longbridge.com/en/news/303016405.md)
- [AppLovin Corporation $APP Stock Purchased by Hedeker Wealth LLC](https://longbridge.com/en/news/303049441.md)
- [I'd Buy Half a Position in Amazon Stock Before Its Oct. 29 Report -- and Half After](https://longbridge.com/en/news/303054275.md)
- [Google's privacy policy lets connected Gmail and Photos data personalize ads](https://longbridge.com/en/news/302987424.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**